OGT Releases New Hematological Malignancy Array

Oxford Gene Technology (OGT) has released the first in a number of new microarrays for use in cancer research. The CytoSureTM Haematological Cancer +SNP array is optimized for the study of Chronic Lymphocytic Leukaemia (CLL), Multiple Myeloma (MM), Myeloproliferative Neoplasms (MPN) and Myelodysplastic Syndromes (MDS).

The new CytoSure™ Haematological Cancer +SNP array offers confident detection of both copy number variation (CNV) and loss of heterozygosity (LOH) on a single chip for these diseases. This is achieved by utilizing OGT’s novel array design, which combines long oligo array comparative genomic hybridisation (aCGH) probes for CNV detection with fully validated single nucleotide polymorphism (SNP) content for identifying LOH.

The probes on the array have been optimized to target regions known to be important predictors of disease progression and patient prognosis in hematological cancers. This facilitates the rapid, reliable identification of key genomic aberrations, while the complimentary CytoSure Interpret Software allows intuitive, single-click data analysis.

James Clough, Vice President OGT Clinical & Genomic Solutions, commented: “OGT has worked in collaboration with leading researchers to develop the CytoSure Haematological Cancer +SNP array. The new array is the first member of a rapidly expanding portfolio we are developing for the genetic analysis of cancerous lesions, with several other additions set to be released in the near future.”